Quantcast

Latest HBV Stories

2009-07-29 10:19:59

Hepatitis B virus (HBV) infection is a dynamic process with variable biochemical, virological and histological profiles at different stages of the infection, depending on host and viral factors. Furthermore, this profile may change at a variable pace over time. The correlation between detection of T-cell response and HBV load in chronic HBV infection remains unknown. In each of the clinical stages of chronic HBV infection, whether the composition of T-cell subpopulations is different and...

2009-07-15 08:28:14

Prolonged use of highly active antiretroviral therapy (HAART) to treat people infected with both HIV and hepatitis B (HBV) helps to better control the hepatitis B infection and could delay or prevent liver complications, according to a new study by researchers at Wake Forest University School of Medicine.Researchers also found that patients who had higher levels of a common liver enzyme upon beginning treatment for HIV-HBV co-infection were at an increased risk of being diagnosed with...

2009-04-09 09:07:50

Patient-to-patient transmission of hepatitis B virus (HBV) can occur as the result of routine clinical practices incorrectly thought to be risk-free. A review of 33 HBV outbreaks, published in the open access journal BMC Medicine, has shown that the most frequent HBV transmission routes are administration of drugs using multi-vial compounds and capillary blood sampling (e.g. for glucose monitoring) using non-disposable devices. Simone Lanini led a team of researchers from the Istituto...

2009-03-31 08:00:00

FREDERICK, Md., March 31 /PRNewswire/ -- ImQuest Life Sciences today presented important new results on the continued development of the pyrimidinedione small molecules as antiviral agents at the 13th International Symposium on Viral Hepatitis and Liver Disease meeting held last week in Washington D.C. ImQuest's screening efforts have identified ten pyrimidinediones as inhibitors of HBV replication, with two compounds yielding potent inhibition of HBV replication at sub-micromolar...

2008-11-03 09:00:40

Gilead Sciences, a biopharmaceutical company, has presented two-year data from two Phase III pivotal clinical trials, studies 102 and 103, evaluating the safety and efficacy of once-daily Viread among adult patients with chronic hepatitis B virus infection. These new data show that patients who received Viread for up to 96 weeks experienced sustained suppression of hepatitis B virus (HBV) levels in the blood (91% and 78% for Studies 102 and 103, respectively). The studies also show that all...

2008-11-02 12:00:04

Bristol-Myers Squibb Company (NYSE:BMY) today announced data from two separate cohort evaluations, in which long-term treatment with BARACLUDE(R) (entecavir) was associated with improved liver histology, including improvement in fibrosis, in chronic hepatitis B patients. The histology data were presented today at the 59th Annual Meeting of the American Association for the Study of Liver Diseases. New long-term histology results were presented from a cohort of 57 nucleoside-naive patients...

2008-11-01 12:00:15

Gilead Sciences, Inc. (Nasdaq:GILD) today announced the presentation of two-year (96-week) data from two Phase III pivotal clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread(R) (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection. These data will be presented during oral sessions at the annual meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2008) being held this...

2008-10-02 09:00:07

Hepatitis B exposure may increase risk for pancreatic cancer: study WASHINGTON, Oct. 1 (Xinhua) -- In a first-of-its-kind finding, researchers at University of Texas have discovered that exposure to the hepatitis B virus (HBV) may increase the risk of pancreatic cancer. The study, published in the Oct. 1 edition of the Journal of Clinical Oncology, also suggests that patients with this lethal form of cancer treated with chemotherapy may face danger of reactivation of their HBV....

2008-09-04 15:00:36

PLEASANTON, Calif., Sept. 4 /PRNewswire/ -- The U.S. Food & Drug Administration (FDA) has approved the Roche COBAS(R) TaqMan(R) HBV Test, the first assay for quantitating Hepatitis B Virus DNA approved in the U.S. The test uses Roche's real-time PCR technology to quantify the amount of Hepatitis B virus DNA in a patient's blood. Doctors may use viral load testing results to establish a baseline level of infection and during treatment as an aid in assessing individual responses to...

2008-08-18 18:00:48

ViRexx Medical Corp. (TSX: VIR) (AMEX: REX), company focused on developing innovative-targeted therapeutic products that offer better quality of life and a renewed hope for living. Its platform technologies include product candidates for the treatment of Hepatitis B, Hepatitis C, avian influenza viral infections, biodefence and nanoparticle applications, select solid tumors and late-stage ovarian cancer, today announced that it is presenting encouraging results from the laboratory studies on...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.